On September 15, 2026, Fangliang Zhang's long position in GENSCRIPT BIO was passively diluted due to the placing of new shares under the general mandate. The company issued 77,126,000 new shares, resulting in a decrease in the shareholding percentage despite the holding count remaining unchanged at 801.15 million shares.
Prior to the placement, Fangliang Zhang's long position was 801.15 million shares, representing 36.36%; following the placement, the holding remained at 801.15 million shares, with the long position ratio passively diluted to 35.13%.
This involves related parties: Wang Ye.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments